Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This study will test feature enhancements to a behavioral therapy data collection software (Motivity) that will add a new clinical decision support module, called Acuity. Acuity is a Quality Improvement (QI) intervention targeted at Behavior Analysts (BAs) and Behavior Technicians (BTs) that aims to improve the delivery of autism behavioral therapy. Subjects will be staff recruited from existing Motivity customers.
Acuity is intended to provide significant improvements in treatment planning, progress tracking, trend monitoring, and dosage management. If successful, Acuity will provide Applied Behavior Analysis (ABA) practitioners with a higher level of real-time insight into their clinical data, enabling more efficient and productive treatment. Research has shown that first-generation systems fall short in supporting overworked BAs who are overwhelmed with data. Acuity will address critical shortfalls by enabling more agile corrective actions and data-driven planning across multiple aspects of treatment, providing practitioners with new levels of rigorous, real-time insight into their clinical data. Acuity will help BAs establish and adhere to realistic treatment timelines, and will proactively alert the BA to noteworthy trends in the data as they occur, such as learner performance issues, missed dosages, and significant changes in tracked behaviors. In doing so, Acuity will support more responsive and effective treatment.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Acuity-Basic | Other |
| |
| Acuity-Enhanced | Experimental |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Acuity | Behavioral | Enhancement to Motivity product for clinical decision support |
|
| Measure | Description | Time Frame |
|---|---|---|
| Number of participants with improved estimation of Trials to Criterion and Time (days) to Criterion | Does Acuity make initial timeline estimates for sets of targets more accurate? | through study completion, expected to be 18 months from the start of retroactive observation period |
| Increased frequency of changes to programs and prescribed dosages, resulting in reduced Trials to Criterion and Time to Criterion. | Does Acuity result in corrective action being taken more quickly for programs that are off schedule or targets that are exhibiting performance issues? | through study completion, expected to be 18 months from the start of retroactive observation period |
| Increased adherence to prescribed dosage | Does Acuity result in increased adherence to prescribed dosage, as measured by system | through study completion, expected to be 18 months from the start of retroactive observation period |
| Number of participants who find Acuity and its components practical and possible to use, assessed by qualitative measures and system usage tracking | Feasibility - To what extent are Acuity and its components practical or possible to use? | at the end of the study, expected to be 18 months from the start of retroactive observation period |
| Proportion of clinics and providers that actively use Acuity, assessed by system usage tracking. | Adoption - What proportion of clinics and providers are willing to use Acuity and how well do they represent the population of clinics and providers? | at the end of the study, expected to be 18 months from the start of retroactive observation period |
| Number of BAs & BTs who utilize Acuity as intended to provide learners with accurate treatment plans, and achieve expected results, as measured by system usage and qualitative assessment. |
Not provided
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Experiad LLC | Honolulu | Hawaii | 96816 | United States |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D001321 | Autistic Disorder |
| ID | Term |
|---|---|
| D000067877 | Autism Spectrum Disorder |
| D002659 | Child Development Disorders, Pervasive |
| D065886 | Neurodevelopmental Disorders |
| D001523 | Mental Disorders |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Fidelity - the degree to which BAs and BTs use the system as expected, including dosage adherence, treatment planning accuracy, and timely protocol modification. |
| at the end of the study, expected to be 18 months from the start of retroactive observation period |
| Majority of BAs and BTs rate Acuity and its components as attractive, agreeable, or palatable. | Acceptability, as measured by SUS score and SUS Items 1, 5, 6 & 8 collected via online survey at the end of O0 & O1 from both arms. | at the end of the study, expected to be 18 months from the start of retroactive observation period |
| Frequency at which Acuity and its components are rated as suitable, fitting, or proper for achieving the goals set forth in treatment plans, as measured by surveys. | Appropriateness - Same measures captured for all primary & secondary research questions in the Functional Impact Evaluation. Brief online survey with Likert scaled items focused on the providers' assessment of how well Acuity and its components are matched to the challenges of planning and executing Treatment Plans. | at the end of the study, expected to be 18 months from the start of retroactive observation period |